



Patient's Selection and Technical Refinements to Make F-BEVAR Successful

Stéphan Haulon,
J Sobocinski, A Hertault, R Azzaoui

Aortic Center,
CHRU de Lille, France



Disclosures

- Research support, Consulting, IP
 - Cook Medical, GE Healthcare, Bentley



Open vs Endo

Circulation
JOURNAL OF THE AMERICAN HEART ASSOCIATION



Contemporary Analysis of Descending Thoracic and Thoracoabdominal Aneurysm Repair: A Comparison of Endovascular and Open Techniques

Roy K. Greenberg, Qingsheng Lu, Eric E. Roselli, Lars G. Svensson, Michael C. Moon, Adrian V. Hernandez, Joseph Dowdall, Marcelo Cury, Catherine Francis, Kathryn Pfaff, Daniel G. Clair, Kenneth Ouriel and Bruce W. Lytle

Circulation. 2008;118:808-817; originally published online August 4, 2008;
doi: 10.1161/CIRCULATIONAHA.108.769695

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

Table 3. Patient Characteristics for Open and Endovascular Repair Techniques

Patient Characteristics	SR (n=372)	ER (n=352)	P
Age, mean±SD	62.7±13	71.3±12	<0.001
Male gender, %	64	65	0.6
Black, %	10	7	0.1
Smoking, %	54	62	0.03
Diabetes mellitus, %	5	11	0.003
Cardiac			
History of CAD, %	33	50	<0.001
EF, mean±SD*	54.4±8.8	52.5±11.8	0.02
EF <0.30, %	3	6	0.03
Pulmonary			
History of COPD, %	17	30	<0.001
FEV1*	2.2±0.8	1.7±0.8	<0.001
FEV1 <1 L, %*	3	20	<0.001
FEF 25% to 75%*	1.7±0.9	0.9±0.7	<0.001
FEF 25% to 75% <30% of expected, %*	32	52	0.001
History of cancer, %	9	13	0.09
BMI, mean±SD*	27.5±10.2	26.8±5.1	0.4
Renal			
GFR, mean±SD†	77.7±30	66.1±28.5	<0.001
<40, %	9	17	0.001
<60, %	28	40	0.001
Aortic diameter, cm, mean±SD	6.2±1.3	6.3±1.3	0.9
Extent of aneurysm repair, %			
0	36	46	<0.0001
I	14	23	
II	16	5	
III	17	6	
IV	17	20	
Chronic dissections, %	30	13	<0.001
History of surgery for proximal aorta, %	31	18	<0.001
History of surgery for distal aorta, %	16	28	<0.001

	Repair	n	Mortality at 30 days			Mortality at 1 year			SCI	
			n	%*	Rate* *	n	%*	Rate**	n	%
0	ER	163	8	5	0.62	20	12	0.14	1	1
	SR	136	8	4	0.73	15	11	0.13	1	1
I	ER	82	6	7	0.94	15	19 [†]	0.25	8	10
	SR	51	1	2	0.24	2	4	0.04	7	14
II	ER	16	1	6	0.80	5	36	0.45	3	19
	SR	59	10	17	2.36	13	22	0.30	13	22
III	ER	22	2	9	1.16	7	34	0.52	1	5
	SR	62	8	12	1.68	13	21	0.27	6	10
IV	ER	69	3	4	0.55	8	12	0.18	2	3
	SR	64	4	6	0.80	16	22	0.30	1	2
All	ER	352	20	6	0.72	55	16	0.21	15	4
	SR	372	31	7	1.07	59	15	0.19	28	8

Lille Aortic Center

- October 2004 - December 2016
- 468 F-BEVAR
- Mean aneurysm diameter: 60mm (42-103)



Crawford Classification

- Type 1: 11 (2.3 %)
- Type 2: 44 (9.4 %)
- Type 3: 166 (35.5 %)
- Type 5: 14 (3 %)

- Type 4: 138 (29.5 %)
- Juxta+ Pararenals: 95 (20.3 %)



COMORBIDITIES

- ASA 3 & 4: 95%
- CAD: 209 (44 %)
- COPD: 172 (37 %)
- CKD : 112 (24 %)



DEVICE

- Fenestrated grafts: 396 (85 %)
- Branched grafts: 48 (10 %)
- Branched and Fenestrated grafts: 24 (5 %)



PROCEDURE

	PROCEDURE TIME (MIN)	Contrast (ml)	Fluoroscopy time (sec)
AVERAGE	195	129	2579
MEDIAN	180	120	2252
MIN	65	30	338
MAX	675	466	9780



30d MORTALITY

Global	468	5 % (23/462)
< 80y	409	4.2 % (17/404)
≥ 80 y	59	10.3 % (6/58)



30d MORTALITY

Global	468	5% (23/462)
No CKD	356	3,4 % (12/350)
CKD	112	9,8 % (11/112)



30d MORTALITY

Global	468	5 % (23/462)
ASA1	0	
ASA 2	25	4 % (1/25)
ASA 3	419	4.1 % (17/413)
ASA 4	24	20.8 % (5/24)



30d MORTALITY

Global	468	5 % (23/462)
Type I	11	9.1 % (1/11)
Type II	44	9.3 % (4/43)
Type III	166	5.6 % (9/162)
Type IV	138	3.6 % (5/137)
Type V	14	0 %
Juxta + Pararenals	95	4.2 % (4/95)



Spinal Cord Ischaemia

- 18 cases / 468 patients: 3.8 %
 - No recovery: 11 (2.4 %)
 - Partial recovery: 4 (0.9 %)
 - Full recovery: 3 (0.6 %)
- * 30d mortality associated with SCI: 22.2 % (4/18)




Target Vessels Occlusion

Mean FU: 37 months

TOTAL	51/1363 (3.7 %)
RRA	16/402 (4 %)
LRA	15/402 (3.7 %)
SMA	6/326 (1.8 %)
TC	12/212 (5.7 %)
Other fenestrations	2/21 (9.5 %)

Oderich et al, SVS 2016

Variable	All n = 127	Pararenal n = 47	Type IV TAAA n = 42	Type I-III TAAA n = 38	P value
<i>N and (Percent) or Mean $\pm$ Standard Deviation</i>					
Any cause of mortality	0	0	0	0	1
Any major adverse event	27 (21)	10 (21)	9 (21)	8 (21)	1
Estimate blood loss higher than 1000 ml	10 (8)	1 (2)	2 (5)	7 (18)	0.014
Acute Kidney Injury (> 50% decrease in GFR)	12 (9)	4 (9)	6 (14)	2 (5)	0.37
New-Onset Dialysis	1 (1)	1 (2)	0	0	0.42
Myocardial Infarction	9 (7)	4 (9)	4 (10)	1 (3)	0.43
Respiratory failure	4 (3)	1 (2)	1 (2)	2 (5)	0.67
Paraplegia (SCI Grade 3a to 3c)	2 (2)	1 (2)	0	1 (3)	0.59
Stroke	4 (3)	1 (2)	2 (5)	1 (3)	0.76
Bowel ischemia requiring intensification of medical therapy	3 (2)	2 (4)	1 (2)	0	0.44
Postprocedure transfusion	37 (29)	7 (15)	10 (24)	20 (53)	<.001



Outcomes / Patient's Selection

- ASA score
- Age > 80y
- CKD
- Crawford Extension
- SCI



TRANS-ATLANTIC DEBATE

Thomas L. Forbes, MD, and Jean-Baptiste Ricco, MD, PhD, Section Editors

Debate: Whether fenestrated endografts should be limited to a small number of specialized centers

Stéphan Haulon, MD, PhD,^a David Barillà, MD,^a Mark Tyrrell, MD,^b Nikolaos Tsilimparis, MD,^c and Joseph J. Ricotta II, MD, MS,^c *Lille, France; London, United Kingdom; and Atlanta, Ga*

Until fairly recently, experience with advanced endovascular technologies, including fenestrated endovascular repair (FEVAR), has been limited to a relatively small number of practitioners worldwide. Excellent outcomes have been achieved by these accomplished surgeons who, at least initially, have primarily used custom-made devices constructed by a single endograft manufacturer. Access to this technology has been limited by the skills necessary for such procedures and by the customization process with industry partners. However, several issues are changing rapidly with FEVAR. Increasing numbers of surgeons now have the necessary endovascular skills, and off-the-shelf endografts from several manufacturers have become, or are becoming, available. Also, the regulatory landscape is changing with device approval in the United States. Surgeons and patients alike are anticipating the widespread adoption of this advanced technology that will surely benefit increasing numbers of patients. Or will it? Will widespread adoption in a larger number of smaller-volume hospitals, by less experienced surgeons, result in poor patient outcomes, or will excellent results continue with more patients benefitting from these technologic advances? These are important questions to ask before such adoption and are the subject of this debate. (J Vasc Surg 2013;57:875-83.)



Eur J Vasc Endovasc Surg (2015) 49, 248–254

Editor's Choice — The Impact of Early Pelvic and Lower Limb Reperfusion and Attentive Peri-operative Management on the Incidence of Spinal Cord Ischemia During Thoracoabdominal Aortic Aneurysm Endovascular Repair

B. Maurel ^a, N. Delclaux ^a, J. Sobocinski ^a, A. Hertault ^a, T. Martin-Gonzalez ^a, M. Moussa ^a, R. Spear ^a, M. Le Roux ^a, R. Azzaoui ^a, M. Tyrrell ^b, S. Haulon ^{a,*}

^a Aortic Centre, Hôpital Cardiologique, CHRU de Lille, INSERM U1008, Université Lille Nord de France, 59037 Lille Cedex, France

^b King's Health Partners, London, UK

WHAT THIS PAPER ADDS

This paper reports the impact of an optimized spinal cord protection strategy on spinal cord ischemia rates after endovascular thoracoabdominal aneurysm repair performed in a high volume center.




Learning Curve / RESULTS

- In-hospital mortality: 11.6 % in group 1 vs 5.6 % in group 2 (RR = 0.481 [0.17-1.36]; p = 0.09)
- Spinal Cord Ischemia: 14% vs 1.2% (RR = 1.148 [1.016-1.296]; p < 0.001)




INCREASED COMPLEXITY



Courtesy G. Oderich



GE Discovery IGS 730




GE DISCOVERY IGS 730


Literature overview

Where do we stand?


Median DAP ($\text{Gy}\cdot\text{cm}^2$) values reported in the Literature for
complex EVAR procedures
















TrackVision Needle Guidance



TrackVision Needle Guidance



Translumbal Puncture for Retrograde Catheterization of a Kinked Left Renal Stent After Fenestrated Endograft Repair

Journal of Endovascular Therapy

1–6

© The Author(s) 2016

Reprints and permissions:

sagepub.com/journalsPermissions.nav


DOI: 10.1177/1526602816664769



www.jevt.org




Adrien Hertault, MD¹, Rachel E. Clough, MD, PhD¹,
Teresa Martin-Gonzalez, MD, PhD¹, Rafaelle Spear, MD, PhD¹,
Richard Azzaoui, MD¹, Jonathan Sobocinski, MD, PhD¹,
and Stéphan Haulon, MD, PhD¹











(Filt. 1)

FOV: 30x30 cm
RAO: 0.8 deg
CAU: 0.5 deg
L: 44.9 deg
Tilt: 0 deg
Mag = 1.00
FL: ROT:
WW: 256 WL: 128
XA 512x512


Seq: 15
FRAME = 108 / 149







Challenging Anatomies

- Proximal and Distal Sealing
- Narrow true lumen
- Target vessels perfused by false lumen





No Compromise on Proximal Seal - Open Surgery




Post Type A Repair Branched Arch Endograft















Staged Approach


































CONCLUSIONS

- Match mid term outcomes of OS in high risk patients
 - Low risk patients?
 - High volume centers
 - Technical success
 - Peri operative management
-

